Jump to content
helplinedonate
  • Announcements

    • ForumAdmin

      Frequently Asked Questions - Step by step guides

      Do you need assistance registering, logging in, posting, etc? Please visit the all new Frequently Asked Question Forum for step-by-step guides. Click the link below to access these helpful guides. Frequently Asked Questions
    • ForumAdmin

      Recursos Nuevos en Español

      http://www.parkinson.org/ayuda   http://www.parkinson.org/espanol    
    • ForumAdmin

      Línea de Ayuda 1-800-473-4636

      Línea de Ayuda 1-800-473-4636   ¿Qué es la línea de ayuda 1-800-4PD-INFO (473-4636) de la Fundación Nacional de Parkinson? Es un número de teléfono gratuito que ayuda a las personas con la enfermedad de Parkinson, sus familiares, amigos y profesionales de salud, a solucionar diferentes inquietudes.   La línea de ayuda ofrece: Información actualizada Apoyo emocional Referidos a profesionales de salud Recursos comunitarios Amplia variedad de publicaciones gratis    
Sign in to follow this  
Dr. Okun

What's Hot in Parkinson's Disease Blog: Eight Sinemet Rule

Recommended Posts

Dear forum members,

 

Check out Dr. Okun's blog this month:

 

http://www.parkinson.org/Patients/Patients---On-The-Blog.aspx

 

Does the FDA really recommend not to exceed 8 sinemet a day?

Sinemet is a registered trade name by Merck pharmaceutical company located in State of New Jersey, USA, for the combination of L-DOPA and

Carbidopa, w/w 4:1 and 10:1, respectively. The company, actually, uses the FDA recommendation as the information for patients who have

been prescribed one or the other formulation of Sinemet. The interesting point is that at least 75 mg Carbidopa/daily is necessary to

complete blockage of aromatic aminoacids decarboxylase on periphery (outside of CNS)and to prevent nausea and vomiting caused by L-DOPA

alone. This combination has effectively permitted to considerable decrease the dose of L-DOPA needed for substitutional therapy of PDs.

gmk

Share this post


Link to post
Share on other sites
Sign in to follow this  

×